Investigation of the metabolism of the selective androgen receptor modulator LGD‐4033 in equine urine, plasma and hair following oral administration
- 26 October 2019
- journal article
- research article
- Published by Wiley in Drug Testing and Analysis
- Vol. 12 (2) , 247-260
Abstract
LGD‐4033 is one of a number of selective androgen receptor modulators (SARMs) that are being developed by the pharmaceutical industry to provide the therapeutic benefits of anabolic androgenic steroids, without the less desirable side effects. Though not available therapeutically, SARMs are available for purchase online as supplement products. The potential for performance enhancing effects associated with these products makes them a significant concern with regards to doping control in sports. The purpose of this study was to investigate the metabolism of LGD‐4033 in the horse following oral administration, in order to identify the most appropriate analytical targets for doping control laboratories. LGD‐4033 was orally administered to two Thoroughbred horses and urine, plasma and hair samples were collected and analysed for parent drug and metabolites. LC‐HRMS was used for metabolite identification in urine and plasma. Eight metabolites were detected in urine, five of which were excreted only as phase II conjugates, with the longest detection time being observed for di‐ and tri‐hydroxylated metabolites. The parent compound could only be detected in urine in the conjugated fraction. Seven metabolites were detected in plasma along with the parent compound where mono‐hydroxylated metabolites provided the longest duration of detection. Preliminary investigations with hair samples using LC–MS/MS analysis indicated the presence of trace amounts of the parent compound and one of the mono‐hydroxylated metabolites. In vitro incubation of LGD‐4033 with equine liver microsomes was also performed for comparison, yielding 11 phase I metabolites. All of the metabolites observed in vivo were also observed in vitro.Keywords
This publication has 21 references indexed in Scilit:
- Detection of SARMs in doping control analysisMolecular and Cellular Endocrinology, 2018
- Detection of LGD‐4033 and its metabolites in athlete urine samplesDrug Testing and Analysis, 2016
- Identification of Selected in vitro-Generated Phase-I Metabolites of the Steroidal Selective Androgen Receptor Modulator MK-0773 for Doping Control PurposesEuropean Journal of Mass Spectrometry, 2016
- Characterization of a non‐approved selective androgen receptor modulator drug candidate sold via the Internet and identification of in vitro generated phase‐I metabolites for human sports drug testingRapid Communications in Mass Spectrometry, 2015
- Characterization of equine urinary metabolites of selective androgen receptor modulators (SARMs) S1, S4 and S22 for doping control purposesDrug Testing and Analysis, 2015
- Liquid Chromatography-High Resolution/High Accuracy (Tandem) Mass Spectrometry-Based Identification of in vivo Generated Metabolites of the Selective Androgen Receptor Modulator ACP-105 for Doping Control PurposesEuropean Journal of Mass Spectrometry, 2014
- The Safety, Pharmacokinetics, and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young MenThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2010
- The use ofin vitrotechnologies coupled with high resolution accurate mass LC‐MS for studying drug metabolism in equine drug surveillanceDrug Testing and Analysis, 2010
- Selective androgen receptor modulators as function promoting therapiesCurrent Opinion in Clinical Nutrition and Metabolic Care, 2009
- Drug Insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and agingNature Clinical Practice Endocrinology & Metabolism, 2006